BAX Baxter International Inc.

Baxter Launches DeviceVue Advanced Asset Tracking System for Sigma Spectrum Infusion System

Baxter International Inc. (NYSE: BAX), a leader in innovative technology for medication delivery, today announced the launch of DeviceVue, a comprehensive asset tracking solution available exclusively to hospitals using the Sigma Spectrum Infusion System. Designed to help enhance clinical and hospital efficiency, DeviceVue helps enable clinicians and biomedical engineers to quickly find unused pumps by viewing pump location and status data from their PC, iPad® or iPhone®. With DeviceVue, Baxter is the first and only smart infusion pump manufacturer to offer a tagless, end-to-end asset tracking application.

“Healthcare leaders today are required to deliver clinical and financial return on every dollar spent,” said Scott Luce, general manager, U.S. Hospital Products, Baxter. “Baxter is committed to continually enhancing the award-winning Sigma Spectrum Infusion System through technologies like DeviceVue that drive operational efficiencies and help facilities maximize clinical value.”

In place of the cost and labor associated with purchasing and installing external radio frequency identification (RFID) tags, DeviceVue receives a signal from the pump’s wireless radio that provides location data, whether the pump is in use, and the status of the pump battery, wireless network connection, and drug library. This data is sent in near real-time to the DeviceVue PC or mobile application.

DeviceVue is currently in use at multiple health systems across the country, including Mississippi Baptist Medical Center in Jackson, Miss., a 564-bed, Magnet®-recognized facility. The Magnet designation represents the highest distinction for nursing excellence and patient care.

In addition to asset tracking, DeviceVue’s utilization reporting can help hospitals reduce costs by ensuring as many pumps as possible are put to use, while the ability to search for specific pumps by serial number can help biomedical engineers dramatically reduce the amount of time required to perform preventive maintenance.

For more information on the Sigma Spectrum Infusion System, please visit www.sigmapumps.com.

About Sigma Spectrum Infusion System

Sigma Spectrum’s hardware works in concert with the pump’s software to encourage use of innovative features that are designed to help enhance patient safety and clinician efficiency. For example, the pumps automatically default to the installed drug library without requiring clinicians to take extra steps to “opt-in,” and drug library updates can be delivered wirelessly to pumps in the facility without interrupting clinical workflow. Sigma Spectrum is the only pump to include a built-in Dose/Rate Change Error Prevention Feature, which helps clinicians protect high-risk infusions during titrations, and allows pharmacists to customize dose change limits for individual drugs. Sigma Spectrum also includes features like: integration with electronic health record (EHR) systems—including Cerner® and Epic®—to help streamline clinical workflow and improve accuracy of IV infusion documentation; DeviceVue, a tagless, end-to-end asset tracking solution that can help provide a significant boost to both clinical and operational efficiency; enhanced data analytics and use of single set technology that can help yield up to 53 percent cost savings in IV tubing sets and 30 percent reduction in IV tubing use.1

DeviceVue will work with any V8 and V6 Sigma Spectrum infusion pump that has a wireless radio and Master Drug Library v6.5.6 or later.

Pumps must have at least 25% charge in order to continue providing data to DeviceVue.

Sigma Spectrum Infusion System is Rx Only. For the safe and proper use of this device, refer to the appropriate operator’s manuals.

About Baxter

Baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; surgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.

This release includes forward-looking statements concerning Baxter's DeviceVue and Sigma Spectrum Infusion System and related performance data, including anticipated benefits associated with their use. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; demand for and market acceptance of new and existing products; product development risks; the impact of competitive products and pricing; product quality, manufacturing or supply issues; patient safety issues; breaches or failures of the company’s information technology systems; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.

Baxter and Sigma Spectrum are trademarks of Baxter International Inc.

iPad and iPhone are registered trademarks of Apple Inc.

The Magnet Recognition Program®, ANCC Magnet Recognition®, Magnet®, ANCC National Magnet Conference®, and Journey to Magnet Excellence® names and logos are registered trademarks of the American Nurses Credentialing Center. All rights reserved.

Cerner is a registered trademark of Cerner Corporation and/or its subsidiaries.

Epic is a registered trademark of Epic Systems Corporation in the United States and/or in other countries.

1 Data on File. Baxter Healthcare Corporation. Total cost of ownership standard set technology inventory and cost reduction data 2011- 2013. *Data provided by these facilities. Baxter makes no guarantee of cost savings.

EN
27/09/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Baxter International Inc.

Moody's Ratings assigns Baa3 rating to Baxter's senior notes; outlook ...

Moody's Ratings (Moody's) assigned a Baa3 rating to the proposed new senior unsecured notes issuance of Baxter International Inc. (Baxter). At the same time, we assigned a (P)Baa3 rating to Baxter's senior unsecured shelf registration. There are no changes to Baxter's existing ratings including the ...

Baxter International Inc.: Update following downgrade to Baa3

Our credit view of this issuer reflects its elevated financial leverage, with delays in reaching previously stated deleveraging targets.

Moody's Ratings downgrades Baxter to Baa3/P-3; outlook is stable

Moody's Ratings (Moody's) downgraded the ratings of Baxter International Inc. (Baxter) including the senior unsecured ratings to Baa3 from Baa2 and the commercial paper rating to Prime-3 from Prime-2. The outlook is stable. Previously, the ratings were on review for downgrade. This action concludes ...

Moody's Ratings reviews Baxter's Baa2/P-2 ratings for downgrade

Moody's Ratings (Moody's) placed the ratings of Baxter International Inc. (Baxter) on review for downgrade. The ratings placed on review include the Baa2 senior unsecured ratings and Prime-2 commercial paper rating. Previously, the outlook was negative. The review is prompted by operating pressure...

Moody's Ratings affirms Baxter at Baa2; revises outlook to negative fr...

Moody's Ratings (Moody's) affirmed Baxter International Inc.'s (Baxter) ratings, including its Baa2 senior unsecured ratings and Prime-2 commercial paper rating. At the same time, we revised the outlook to negative from stable. The ratings affirmation considers Baxter's good scale and diversity as...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch